OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Paulson on the Importance of Biomarker Testing in Oncology

February 22nd 2020

R. Steven Paulson, MD, discusses the importance of molecular testing in the era of precision medicine in oncology.

Dr. Hays on Immunotherapy Research in Gynecologic Cancer

February 22nd 2020

John Hays, MD, PhD, discusses immunotherapy research in gynecologic cancer.

Dr. Coleman on the Safety Profile of Veliparib in Ovarian Cancer

February 22nd 2020

Robert L. Coleman, MD, FACOG, FACS, discusses the safety profile of veliparib examined in the VELIA trial looking at patients with high-grade serous ovarian cancer.

Dr. Rossetti on Symptom Management for Patients With MPNs

February 22nd 2020

James M. Rossetti, DO, discusses symptom management for patients with myeloproliferative neoplasms.

Dr. Michaelis on Treating Patients With Myelofibrosis and Anemia

February 22nd 2020

Laura C. Michaelis, MD, discusses the treatment of patients with myelofibrosis and anemia.

Dr. Rampal on Investigational Agents in MPNs

February 22nd 2020

Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.

Dr. Armstrong on the Rationale of the PROPHECY Trial in mCRPC

February 21st 2020

Andrew J. Armstrong, MD, discusses the rationale of the PROPHECY trial in metastatic castration-resistant prostate cancer.

Dr. Tan on the Risk of Novel Coronavirus for Patients With Cancer

February 21st 2020

Christina Tan, MD, MPH, discusses the potential impact of the novel coronavirus on patients with cancer.

Dr. Heyman on Frontline Treatment Options in Follicular Lymphoma

February 21st 2020

Benjamin Heyman, MD, discusses frontline treatment options for patients with follicular lymphoma.

Dr. Kuykendall on Toxicity Profiles of Ruxolitinib and Fedratinib in Myelofibrosis

February 21st 2020

Andrew T. Kuykendall, MD, discusses the toxicity profiles of ruxolitinib and fedratinib in myelofibrosis.

Dr. Kremyanskaya on Responses With CPI-0610 in Patients With Myelofibrosis

February 21st 2020

Marina Kremyanskaya, MD, PhD, discusses responses with CPI-0610 in patients with myelofibrosis.

Dr. Garcia on the Role of Navitoclax in Myelofibrosis

February 21st 2020

Jacqueline S. Garcia, MD,discusses how navitoclax differs from other agents in primary or secondary myelofibrosis.

Dr. Danilov on ELEVATE-TN Trial Results in CLL

February 21st 2020

Alexey V. Danilov, MD, PhD, discusses the findings of the phase III ELEVATE-TN trial in treatment-naïve patients with chronic lymphocytic leukemia.

Dr. Fendler on Clinical Need for 68GA-PSMA-11 PET in Prostate Cancer

February 21st 2020

Wolfgang Fendler, MD, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, discusses the clinical need for 68Ga-PSMA-11 PET in biochemically recurrent prostate cancer.

Dr. Emens on Combining Checkpoint Inhibitors With PARP Inhibitors in Ovarian Cancer

February 21st 2020

Leisha A. Emens, MD, PhD, discusses the combination of checkpoint inhibitors and PARP inhibitors in ovarian cancer.

Dr. Cercek on Targeted Strategies in BRAF-Mutant mCRC

February 21st 2020

Andrea Cercek, MD, discusses targeted strategies in BRAF-mutant metastatic colorectal cancer.

Dr. Lopategui on the Use of Liquid Biopsies in Lung Cancer

February 21st 2020

Jean Lopategui, MD, discusses the use of liquid biopsies in lung cancer.

Dr. Denduluri on the Use of the Oncotype DX Assay in Early-Stage HR+/HER2- Breast Cancer

February 21st 2020

Neelima Denduluri, MD, discusses the use of the Oncotype DX assay in early-stage hormone receptor–positive, HER2-negative breast cancer.

Dr. Graff on the KEYNOTE-199 Trial Design in Castration-Resistant Prostate Cancer

February 20th 2020

Julie N. Graff, MD, discusses the multi-cohort, phase II KEYNOTE-199 study examining patients with metastatic castration-resistant prostate cancer.

Dr. Woyach on Ibrutinib Regimens in Frontline CLL

February 20th 2020

Jennifer Woyach, MD, discusses the findings of the ALLIANCE AO41202 and ECOG-ACRIN E1912 trials in the frontline treatment for patients with chronic lymphocytic leukemia.